Regulatory Story
Company Horizon Discovery Group plc
Headline Additional Block Listing and Total Voting Rights
Released 15:22 22-Oct-2019
Number 7539Q

RNS Number : 7539Q
Horizon Discovery Group plc
22 October 2019


Horizon Discovery Group plc

Additional Block Listing and Total Voting Rights

22 October 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon") announces that an application has been made to the London Stock Exchange for a block admission of 1,500,000 new ordinary shares of 1p each in the Capital of the Company ("New Ordinary Shares") to be admitted to trading on AIM (the "Block Admission"). It is expected that Admission will occur on 28 October 2019.

These New Ordinary Shares shall be issued and allotted from time to time pursuant to the exercise of share options under the following employee share plans: 

·     Horizon Discovery Group plc Long Term Incentive Plan (up to 500,000 shares)

·     Horizon Discovery 2014 Sharesave Scheme (up to 500,000 shares)

·     Horizon Discovery Group plc US Employee Stock Purchase Plan (up to 500,000 shares)

The new ordinary shares, when issued, will rank pari passu with the existing shares of the Company.

Total voting rights

As at 22 October 2019, the Company's issued share capital consisted of 150,481,842 ordinary shares of 1p each with voting rights. The Company does not hold any ordinary shares in Treasury.

The total number of voting rights in the Company is therefore 150,481,842.

Following admission of the New Ordinary Shares, the Company's issued share capital will remain unchanged at 150,481,842. The Company will continue to make six-monthly announcements of the utilisation of the Block Admission, in line with its obligations under AIM Rule 29.

The figure 150,481,842 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Horizon Discovery Group plc under the FCA's Disclosure and Transparency Rules.


For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Jon Davies, Head of Investor Relations

Tel: +44 (0) 1223 655 580


Numis Securities Limited (Broker and NOMAD)

Freddie Barnfield / Tom Ballard / Duncan Monteith

Tel: +44 (0) 207 260 1000



Consilium Strategic Communications (UK Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5700



Westwicke, an ICR Company (US Investor Relations)

Stephanie Carrington

Tel. 646-277-1282





About Horizon Discovery Group plc


Horizon Discovery Group plc (LSE: HZD) ("Horizon") drives the application of gene editing and gene modulation within the global life science market - supporting scientists on the path from research to therapy.


Built upon more than a decade of experience in the engineering of cell lines, Horizon offers an unmatched portfolio of tools and services to help scientists gain a greater understanding of gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.


Horizon's solutions enable almost any gene to be altered, or its function modulated, in human and other mammalian cell lines.


The Company's customers include many of the world's foremost academic institutes, global biopharmaceutical and biotechnology companies as well as clinical diagnostic laboratories. Insight into the challenges faced by these organizations enables Horizon to focus efforts on development of innovative solutions that not only differentiate the Company's offering, but also fuel development of the next wave of precision medicines.


Horizon is headquartered in Cambridge, UK with offices in USA and Japan.  The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.